BUY Aurobindo Pharma — Sandip Sabharwal, 05 Aug 2026

BUYAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

bySandip SabharwalHorizon: NA (inferred Swing (≤2wk))5 Aug 2026via ET Now

Entry₹1,625Inferred

Target₹1,700

Total upside +4.62%

Stop lossNot given

At expiry₹1,624.519 Aug 2026, 3:30 pm

Expired-0.03%auction close

Follow Sandip Sabharwal for new callsGet alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 1 active Swing call on AUROPHARMA See 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 19 Aug 2026

15 supporting4 neutral3 opposing

Supports the BUY call (15)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·18 Aug · yesterday

Aurobindo Pharma Ltd has incorporated a new wholly owned subsidiary in India named 'Auropharm Overseas Limited'. The subsidiary will undertake manufacturing and marketing operations.

BSE · Company Update·13 Aug · 5d ago

Aurobindo Pharma Expands Margins as Sales Grow

NewsGoogle News·12 Aug · 6d ago

Results: Aurobindo Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

NewsGoogle News·8 Aug · 2w ago

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·7 Aug · 2w ago

Neutral / worth noting (4)

Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.

NSE · Press Release·5 Aug · 2w ago

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · 2w ago

Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries

NewsCnbc-Tv18·24 Jul · 4w ago

Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million

NewsCnbc-Tv18·23 Jul · 4w ago

Weighs against the BUY call (3)

Aurobindo Pharma shares in focus after USFDA closes Raleigh unit inspection with 11 observations

NewsCnbc-Tv18·17 Aug · 2d ago

Aurobindo Pharma shares fall after USFDA issues warning letter to Eugia's Unit 1

NewsCnbc-Tv18·14 Aug · 5d ago

1 advisor has an active short-term SELL call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·6 Aug · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Sandip Sabharwal

Every call and its outcome